@article{45bc0e3b6cc04b60aa64e31cc5e5e0c6,
title = " NCCN guidelines {\textregistered} insights non–small cell lung cancer, version 5.2018 featured updates to the NCCN guidelines ",
abstract = "The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the targeted therapy and immunotherapy sections in the NCCN Guidelines. For the 2018 update, a new section on biomarkers was added.",
author = "Ettinger, {David S.} and Aisner, {Dara L.} and Wood, {Douglas E.} and Wallace Akerley and Jessica Bauman and Chang, {Joe Y.} and Chirieac, {Lucian R.} and D{\textquoteright}Amico, {Thomas A.} and Dilling, {Thomas J.} and Michael Dobelbower and Ramaswamy Govindan and Gubens, {Matthew A.} and Mark Hennon and Leora Horn and Lackner, {Rudy P.} and Michael Lanuti and Leal, {Ticiana A.} and Rogerio Lilenbaum and Jules Lin and Loo, {Billy W.} and Renato Martins and Otterson, {Gregory A.} and Patel, {Sandip P.} and Karen Reckamp and Riely, {Gregory J.} and Schild, {Steven E.} and Shapiro, {Theresa A.} and James Stevenson and Swanson, {Scott J.} and Kurt Tauer and Yang, {Stephen C.} and Kristina Gregory and Miranda Hughes",
note = "Funding Information: This activity is supported by educational grants from AstraZeneca, Celldex Therapeutics, Celgene Corporation, Genentech, Jazz Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, and Seattle Genetics, Inc. This activity is supported by independent educational grants from AbbVie, Merck & Co., Inc. and NOVOCURE. Publisher Copyright: {\textcopyright} JNCCN—Journal of the National Comprehensive Cancer Network.",
year = "2018",
month = jul,
day = "1",
doi = "10.6004/jnccn.2018.0062",
language = "English (US)",
volume = "16",
pages = "807--821",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "7",
}